Amikacin was evaluated in vitro by agar dilution testing against 148 different clinical isolates of cephalothin-resistant Enterobacteriaceae and Pseudomonas aeruginosa in parallel with cephalothin, cefoxitin, moxalactam, N-formimidoyl thienamycin, ceftriaxone, and cefmenoxime. Cefsulodin was also evaluated against 39 isolates of P. aeruginosa. More than 80% of all isolates tested were also gentamicin resistant, as determined by disk testing. Moxalactam and amikacin had comparable high activities against Proteus species, Escherichia coli, Serratia species, and Providencia species, and both amikacin and N-formimidoyl thienamycin had comparably high activities against the Klebsiella-Enterobacter group. N-Formimidoyl thienamycin was the most active agent against P. aeruginosa, followed by cefsulodin and amikacin.
It is well known that the patterns of resistance in nosocomial bacterial pathogens change (7) . Clearly, members of the Enterobacteriaceae and Pseudomonas aeruginosa appear to show increasing resistance to gentamicin and other agents (8, 13, 16, 17, 30) ; amikacin has been shown to be the most effective alternative aminoglycoside in vitro (11, 15) . Recently, a plethora of new antimicrobial agents has been investigated in order to meet the challenge of increasing resistance and to offer agents with less potential for nephrotoxicity and ototoxicity. Moxalactam, which is a 1-oxa cephalosporin (18) with a broad spectrum of activity against most gram-positive and gram-negative bacteria, including staphylococci and anaerobic organisms (2, 6, 14, 18, 24, 29) , has recently been introduced for clinical use.
Agents which have been investigated include the carbapenem N-formimidoyl thienamycin (MK0787), which differs from cephalosporins by its 6-a-hydroxyethyl side chain and by the absence of sulfur on the secondary ring (9) . NFormimidoyl thienamycin has demonstrated competitive inhibition against many P-lactamases (23) and in initial studies seemed very active against most gram-positive and gramnegative organisms (11, 22, 28) . Ceftriaxone (Ro 13-9904) and cefmenoxime (SCE-1365) are aminothiazolyl cephalosporins. Ceftriaxone demonstrates good activity against Haemophilus sp., Neiserria gonorrheae, and Neisseria meningitidis and is generally as active as cefotaxime and moxalactam against members of the Enterobacteriaceae (4, 19) . Broad in vitro activity has also been observed with cefmenoxime (25, 27) . Cefsulodin was first introduced as an antipseudomonal cephalosporin (26) and, compared with other cephalosporins, is less active than ceftazidime but more active than cefoperazone or cefmenoxime against P. aeruginosa (10, 26, 27) .
The aim of the present study was to compare four new P-lactam agents with moxalactam, cefoxitin, and amikacin by using multiply drugresistant nosocomial gram-negative bacilli.
MATERIALS AND METHODS The clinical isolates were selected from a pool of Enterobacteriaceae and P. aeruginosa isolates collected from the Wadsworth Veterans Administration Medical Center from 1975 through August 1981 and found to be resistant to cephalothin by standardized disk testing (3). Each isolate was from a different patient and was identified by standard criteria (12 Amikacin was supplied by Bristol Laboratories, cephalothin and moxalactam were supplied by Eli Lilly & Co., cefoxitin and N-formimidoyl thienamycin were supplied by Merck Sharp & Dohme, ceftriaxone was supplied by Hoffmann-La Roche Inc., and cefmenoxime and cefsulodin were supplied by Abbott Laboratories.
The magnesium content of the liquid obtained by freeze-thaw extraction of the media (5) was 1.56 to 1.95 mg/dl (mean ± standard deviation, 1.75 ± 0.10 mg/dl), as measured by atomic absorption spectrophotometry. As determined by a similar analysis, the calcium content was 2.89 ± 0.30 mg/dl (range, 2.42 to 3.83 mg/dl).
The minimal inhibitory concentration (MIC) was defined as the lowest concentration of antibiotic showing only a haze, one colony, or no growth after 18 h of incubation (5) . Only organisms with a cephalothin MIC of .32 ,g/ml as determined by agar dilution testing were included (1) . A total of 148 isolates fulfilled these criteria. Reference strains of Escherichia coli (ATCC 25922) and Staphylococcus aureus (ATCC 25923) were included in parallel tests; these strains had amikacin MICs of 1 and 2 jig/ml, respectively, and cephalothin MICs of 16 and <1 ,ug/ml, respectively.
Susceptibility to an antibiotic was based upon inhibition of an isolate at or below the peak serum levels of the antibiotic achieved in clinical use or in preclinical studies with volunteers. The following MICs in agar were considered as showing susceptibility: amikacin, <16 jig/ml; cephalothin, <16 ,ug/ml (1); cefoxitin, '32 p.g/ml; moxalactam, c32 jig/ml; N-formimidoyl thienamycin, c32 ,ug/ml; ceftriaxone, c32 j±g/ml; cefmenoxime, c32 jig/ml; cefsulodin, s32 j.g/ml. RESULTS P. aeruginosa. N-Formimidoyl thienamycin showed the greatest degree of in vitro activity. A total of 97% of the strains were inhibited by a concentration of 32 ,ug/ml; this included several isolates that were resistant to amikacin. The anti-pseudomonal cephalosporin cefsulodin showed somewhat less activity, with 56% of the strains susceptible at a concentration of 16 ,ug/ml and 72% susceptible at a concentration of 32 ,ug/ ml. In comparison, amikacin inhibited only 50o of the isolates at a concentration of 16 ,ug/ml, whereas 32 ,ug of cefmenoxime inhibited 50% of the isolates. Only 36% of the isolates were inhibited by moxalactam, and 26% were inhibited by 32 ,g of ceftriaxone per ml (Table 1) .
Serratia species. Amikacin and moxalactam demonstrated considerable activity, with 100% of the isolates susceptible to 16 ,ug of amikacin per ml and 97.5% susceptible to 32 ,ug of moxalactam per ml. Cefmenoxime, N-formimidoyl thienamycin, cefoxitin, and ceftriaxone showed less activity; 40% of the isolates were susceptible at concentrations of 32 ,ug/ml. Klebsiella-Enterobacter group. Amikacin showed the most activity, closely paralleled by N-formimidoyl thienamycin. Cefmenoxime, ceftriaxone, and moxalactam inhibited 40 to 60% of the isolates at concentrations of 32 ,ug/ml, and cefoxitin showed poor activity.
Providencia sp. Moxalactam and amikacin were the most active antibiotics in vitro; both of these drugs suppressed 100% of the strains at concentrations of 16 ,g/ml. However, amikacin was more active at lower concentrations; more than 50% of the isolates were inhibited at a concentration of 1 ,ug/ml. Ceftriaxone and Nformimidoyl thienamycin were equally effective, with 100% of the isolates inhibited by concentrations of 32 ,ug/ml, and cefoxitin did almost as well, with 84% of the isolates inhibited by a concentration of 32 p.g/ml. Cefmenoxime active against Providencia, Proteus, and E. coli. Cefsulodin showed moderate activity against P. aeruginosa. Both ceftriaxone and cefmenoxime (aminothiazolyl synthetic cephalosporins) have demonstrated P-lactamase resistance, apparently due to their aminothiazolyl side chains (25) . Cefsulodin is also resistant to ,-lactamases. Ceftriaxone has shown as good activity against Enterobacteriaceae as cefotaxime and moxalactam (4, 19) . Cefmenoxime also has demonstrated broad activity against members of the Enterobacteriaceae and has done well in a mouse model for Klebsiella pneumoniae and Proteus mirabilis urinary infections (25) . There may be synergy between cefmenoxime and gentamicin, as with other P-lactam agents and aminoglycosides against Enterobacter or P. aeruginosa (20) . Cefsulodin, which is very promising as an agent against P. aeruginosa (26, 27) , showed less activity than ceftazidime in one study (27) and less activity than N-formimidoyl thienamycin in this study. Moxalactam, which has a methoxyl group at the 7-a position of the cephem nucleus (like cefoxitin) and an oxygen moi-VOL. 21, 1982 on August 14, 2017 by guest http://aac.asm.org/ Downloaded from ety replacing the sulfur at the 1-position, is also resistant to 3-lactamases and showed considerable activity in this study.
N-Formimidoyl thienamycin is a stabilized derivative of thienamycin and has a half-life in vivo similar to the half-lives of other cephalosporins (-1 to 2 h) (9, 11). The ,B-lactamase resistance of N-formimidoyl thienamycin is secondary to its 6-oa-hydroxyethyl side chain and is caused by the absence of a sulfur on the secondary ring (9) . N-Formimidoyl thienamycin also demonstrated competitive inhibition against many 1-lactamases, much like clavulanic acid (23) , and compared with other ,3-lactam antibiotics, seems more active against Staphylococcus, enterococci, Bacteroides fragilis, and P. aeruginosa (11, 22, 28) .
In this study, N-formimidoyl thienamycin was unequivocally the most active agent against P. aeruginosa and had activity similar to the activities of other newer cephalosporins against members of the Enterobacteriaceae. Even We thank Jack Coburn for the divalent cation determinations.
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